Abciximab to Prevent Vessel Closure After Angioplasty
Abciximab (ab sik si mab; ReoPro - Centocor), the Fab (fragment antigen binding) fragment of the chimeric human-murine monoclonal antibody 7E3 (c7E3 Fab), has been approved by the US Food and Drug Administration as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA) to prevent abrupt closure of the treated coronary vessel....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Abciximab to Prevent Vessel Closure After Angioplasty
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 950
Article Code: 950b
Date: June 9, 1995
Volume: 37
Pages: 52-53
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 950
Article Code: 950b
Date: June 9, 1995
Volume: 37
Pages: 52-53
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)